Key Highlights
- Citigroup’s Geoff Meacham established the highest Wall Street price target on LLY at $1,600, suggesting 45% potential upside.
- Berenberg raised LLY to Buy from Hold with a $1,400 target, forecasting approximately 25% appreciation.
- Shares of LLY reached $1,138, posting a 2% gain during Tuesday’s trading session.
- The pharmaceutical giant commands 60% of the global weight-loss medication market, generating $14.9 billion quarterly from obesity and diabetes products.
- Wall Street consensus shows Strong Buy with 20 analysts assigning an average target of $1,375.78.
Shares of Eli Lilly are capturing significant Wall Street interest following a pair of analyst upgrades released in rapid succession.
Geoff Meacham of Citigroup established a $1,600 price objective for LLY, representing the most optimistic forecast among Wall Street analysts. This target suggests approximately 45% appreciation potential from the stock’s present trading level of $1,138.
Meacham, who holds a five-star analyst rating with a 59% accuracy record, maintained his Buy recommendation while raising the target. His bullish perspective centers on the company’s commanding position in the weight-loss pharmaceutical sector.
The Indianapolis-based pharmaceutical company controls 60% of the worldwide weight-loss drug market. Its flagship obesity and diabetes medications, Zepbound and Mounjaro, are currently producing $14.9 billion in aggregate quarterly revenue.
Meacham further observed that LLY shares have declined 8% during the previous month, presenting what he characterizes as an attractive entry point for long-term investors.
Berenberg Shifts to Bullish Stance
Berenberg elevated LLY to Buy from Hold on Tuesday while increasing its price objective to $1,400 from $1,220. The investment firm anticipates roughly 25% appreciation from present valuation levels.
According to Berenberg, its 2026 return on research investment assessment validates Eli Lilly’s historical performance in generating superior shareholder returns. The firm also anticipates the pharmaceutical company will exceed its fiscal 2026 financial guidance.
The research note identified a near-term catalyst: anticipated diabetes approval for Foundayo, Eli Lilly’s oral GLP-1 medication. Foundayo generated approximately $100 million in Q2 2026 revenue, with accelerated growth projected following complete regulatory approval.
Berenberg additionally emphasized the company’s robust pipeline investments, observing that numerous developmental compounds possess multibillion-dollar revenue potential. The pharmaceutical giant has allocated approximately $60 billion across more than 25 business development transactions year-to-date.
Broad Analyst Support Continues
Wall Street analysts have assigned LLY a consensus Strong Buy rating, with 20 analysts covering the stock. The ratings distribution includes 18 Buy recommendations and two Hold ratings. The collective average price target stands at $1,375.78, indicating approximately 12% upside potential from current trading levels.
BMO Capital and JPMorgan have both reaffirmed positive outlooks on LLY in recent weeks. Both financial institutions maintain $1,400 price objectives, emphasizing expansion opportunities in the incretin therapeutic category.
Eli Lilly’s fundamental performance supports the optimistic analyst sentiment. The corporation delivered nearly 50% revenue expansion over the trailing twelve-month period and maintains an exceptional Piotroski Score of 9.
The Medicare Bridge initiative is additionally fueling heightened demand for Eli Lilly’s weight-loss medications, according to Berenberg’s analysis.
Competitor Novo Nordisk, controlling a 38% global share of the obesity drug market, recently unveiled a corporate rebrand, transitioning to simply “Novo.” The Danish pharmaceutical company plans to present a comprehensive strategic roadmap at its Capital Markets Day event scheduled for September 21.
Eli Lilly has also announced plans to acquire Merida Biosciences for approximately $2.875 billion in cash, a transaction designed to enhance its autoimmune and allergic disease treatment portfolio.
LLY concluded Tuesday’s session at $1,138.28, advancing $22.58, representing a 2.02% gain for the day.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
